Heart pill approval a much-needed win for AZ

Share this article:

AstraZeneca said it won approval today for Epanova, a treatment for patients with severe hypertriglyceridemia.

It's the first prescription omega-3 with a two-capsule, once-a-day dosing option, AZ said, something that could give it an edge among fish oil-based cardiovascular pills like GSK's Lovaza and Amarin's Vascepa, as patients with severely high trigs often have other conditions such as diabetes and high blood pressure that require them to take multiple meds.

AZ acquired the omega-3 drug when it bought Omthera Pharmaceuticals last year for up to $443 million. According to Thomson Reuters Pharma, which polled industry analysts, the drug could reach sales of $322 million by 2018.

It came as a small but symbolic win as the British firm fends off a $106-billion takeover attempt from Pfizer.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.